Dr. rer. nat. Michael Meister

Education and Training

Michael Meister is Scientist at the Translational Research Unit (STF) at the Thoraxklinik Heidelberg. He graduated in Biology and conducted his PhD studies at the University of Heidelberg. His postdoctoral research was performed at the Brigham and Women’s Hospital in Boston, USA and the University of Ulm. Since 2004 he is employed at Thoraxklinik Heidelberg.

Expertise

The research of the STF aims to better understand the molecular causes of thoracic diseases. One of the department's main research area is the identification of molecular biomarkers in lung cancer. Michael Meister coordinates and supervises the research activities of the STF in collaboration with the team. He has coordinated both national (LungSys) and international (CANCERALIA, EU-7th) research projects. Currently there is a focus on the establishment of new model systems (organoids, 3D cell culture systems) to research the interaction of different cell types in the tumor context.

• Biomarkers in thoracic diseases
• Prognostic and predictive biomarkers in lung cancer
• Glycodelin in non-small cell lung cancer (NSCLC)

• Lung Cancer
• Platform Biobanking

1. Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, Kazdal D, Allgäuer M, Winter H, Goldmann T, Meister M, Klingmüller U, Schneider MA. The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer. Transl Res. 2024 Oct;272:177-189.
2. Muley T, Schneider MA, Meister M, Thomas M, Heußel CP, Kriegsmann M, Holdenrieder S, Wehnl B, Rolny V, Mang A, Gerber R, Herth F. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. Tumour Biol. 2024;46(s1):S163-S175.
3. Faltus C, Lahnsteiner A, Barrdahl M, Assenov Y, Hüsing A, Bogatyrova O, Laplana M, Johnson T, Muley T, Meister M, Warth A, Thomas M, Plass C, Kaaks R, Risch A. Identification of <i>NHLRC1</i> as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS). Int J Mol Sci. 2022 Sep 14;23(18):10699.
4. Gründing AR, Schneider MA, Richtmann S, Kriegsmann M, Winter H, Martinez- Delgado B, Varona S, Liu B, DeLuca DS, Held J, Wrenger S, Muley T, Meister M, Welte T, Janciauskiene S. Lung Adenocarcinoma Cell Sensitivity to Chemotherapies: A Spotlight on Lipid Droplets and <i>SREBF1</i> Gene. Cancers (Basel). 2022 Sep 14;14(18):4454.
5. Trefzer TB, Schneider MA, Jechow K, Chua RL, Muley T, Winter H, Kriegsmann M, Meister M, Eils R, Conrad C. Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers. Cancer Res. 2022 Sep 2;82(17):3116-3129. PMC9437562.
6. Schneider MA, Richtmann S, Gründing AR, Wrenger S, Welte T, Meister M, Kriegsmann M, Winter H, Muley T, Janciauskiene S. Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma. Int J Oncol. 2022 Apr;60(4):39.
7. Angeles AK, Christopoulos P, Yuan Z, Bauer S, Janke F, Ogrodnik SJ, Reck M, Schlesner M, Meister M, Schneider MA, Dietz S, Stenzinger A, Thomas M, Sültmann H. Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. NPJ Precis Oncol. 2021 Dec 7;5(1):100.
8. Magios N, Bozorgmehr F, Volckmar AL, Kazdal D, Kirchner M, Herth FJ, Heussel CP, Eichhorn F, Meister M, Muley T, Elshafie RA, Fischer JR, Faehling M, Kriegsmann M, Schirmacher P, Bischoff H, Stenzinger A, Thomas M, Christopoulos P. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509.
9. Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2022 Feb;71(2):251-265.
10. Goldmann T, Schmitt B, Müller J, Kröger M, Scheufele S, Marwitz S, Nitschkowski D, Schneider MA, Meister M, Muley T, Thomas M, Kugler C, Rabe KF, Siebert R, Reck M, Ammerpohl O. DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. Clin Epigenetics. 2021 Feb 17;13(1):38.

PubMed Link